ASCO 2026 preview – Celcuity gets a mutant coup
The Viktoria-1 trial of gedatolisib is a hit in PIK3CA-mutant, as well as in wild-type disease.
ASCO 2026 preview – recent wins come under the spotlight
Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
AACR 2026 – Matisse paints a mixed picture for Innate
IPH5201 plus Imfinzi in perioperative NSCLC looks better than some but not other historical studies.
AACR 2026 – Moderna touts first-line data
The IDO/PD-L1 project mRNA-4359 shows early hints in first-line melanoma.
ASCO 2026 preview – Revolution completes its rout
Daraxonrasib scores a plenary session late-breaker.
AACR 2026 – Circle’s focus narrows
First-in-human results prompt a biomarker-defined approach for CID-078.
AACR 2026 – Qilu challenges Torl in Claudin6
The company’s conjugate QLS5132 has produced intriguing, but early results.
